LZLiqun Zou

Liqun Zou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Liqun Zou has a total of 78 co-authors. Here are the top co-authors by number of shared publications:

  • Huijie Zhou

    Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China

    6 shared publications
  • Na Li

    Department of Oncology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China

    6 shared publications
  • Wanchun Wu

    State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China

    6 shared publications
  • Xi Chen

    Department of Medical Oncology of Cancer Center, West China Hospital, Sichuan University, Chengdu, China

    5 shared publications
  • Tian Fang

    Division of Medical Oncology, Cancer Center and State Key Laboratory of Biotherapy, Sichuan University West China Hospital, Chengdu, China

    4 shared publications
  • Kexin Ren

    Division of Medical Oncology, Cancer Center and State Key Laboratory of Biotherapy, Sichuan University West China Hospital, Chengdu, China

    3 shared publications

Latest Publications

  • Open Access

    Synchronous mucosa-associated lymphoid tissue lymphoma in a married couple: a case report

    by Mo Cheng, Yafei Pi, Kexing Ren, Wenke Li, Liqun Zou

    Mucosa-associated lymphoid tissue (MALT) lymphoma represents an indolent form of non-Hodgkin lymphoma, predominantly arising in the gastrointestinal tract, particularly the stomach, with rare occurrences reported in the urinary tract. Its etiology is closely associated with chronic antigenic stimulation, commonly linked to persistent infections such as H. pylori , autoimmune conditions, or underlying genetic susceptibility. This report details a unique case of a married couple diagnosed with primary MALT lymphoma at separate anatomical sites—ileocecal region in the husband and urethra in the wife—within a span of one year. Both individuals attained complete remission following rituximab-based immunotherapy, supplemented by radiotherapy in wife case. The development of lymphoma in married couples, whether presenting with identical or distinct pathological subtypes, is exceptionally uncommon and frequently suggests potential shared environmental or infectious exposures.

  • Open Access

    KPT-330-mediated XPO1 inhibition impairs homologous recombination and enhances radiosensitivity in extranodal NK/T-cell lymphoma

    by Huijie Zhou, Qiuluo Liu, Kexing Ren, Qian Luo, Chunli Yang, Tian Fang, Xi Chen, Liqun Zou

    Background Extranodal NK/T-cell lymphoma (ENKTL) is a rare, aggressive lymphoma in which radioresistance remains a major cause of treatment failure in the relapsed/refractory (R/R) setting. Methods We analysed XPO1 expression in ENKTL and assessed its role in radiosensitization using monoallelic XPO1-knockout models and KPT-330 in vitro and in xenografts. Mechanistic studies focused on the c-Myc–RAD51/CHEK1 axis, and clinical efficacy was evaluated in two R/R patients. Results Immunohistochemistry showed XPO1 overexpression in primary treatment-naïve ENKTL specimens relative to nasal polyp controls, and high XPO1 expression was associated with inferior overall survival. Monoallelic XPO1 knockout impaired homologous recombination (HR) repair, establishing a DNA repair defect exploitable as a radiosensitizing vulnerability. Pharmacologic inhibition of XPO1 with KPT-330 recapitulated these HR defects and synergised with radiotherapy. Mechanistically, KPT-330 disrupts the XPO1–c-Myc–RAD51/CHEK1 axis by blocking c-Myc nuclear export, reducing c-Myc abundance and promoter occupancy at the RAD51 and CHEK1 loci, thereby impairing HR. In two heavily pretreated R/R ENKTL patients, radiotherapy rechallenge plus low-dose KPT-330 achieved one partial response and one complete response with manageable toxicity. Conclusions XPO1 inhibition impairs HR and enhances radiosensitivity by disrupting the c-Myc–RAD51/CHEK1 axis. These findings support prospective evaluation of KPT-330–based radiosensitization in R/R ENKTL. The alternative text for this image may have been generated using AI.

  • CXCR4-targeted [68Ga]Ga-PentixaFor PET/CT improves staging and alters management in marginal zone lymphoma: a prospectively recruited head-to-head study with [18F]FDG

    by Zitong Zhang, Haoyuan Hu, Xin Li, Yongzhao Xiang, Limin Gao, Yunyi Liu, Hexiao Huang, Liqun Zou, Ming Jiang, Chong Jiang, et al.

    Marginal zone lymphoma (MZL) exhibits substantial clinical heterogeneity, necessitating accurate whole-body tumor burden assessment and early risk stratification. However, conventional [18F]FDG PET/CT is limited in both anatomical staging and in vivo biological characterization. This prospectively recruiting study conducted a head-to-head comparison of the CXCR4-targeted tracer [68Ga]Ga-PentixaFor and [18F]FDG in treatment-naïve patients to evaluate their complementary value in improving staging accuracy and their association with early treatment response. Forty-one treatment-naïve MZL patients prospectively underwent dual-tracer PET/CT prior to therapy. Lesion detection rates, stage migration, and management modifications were systematically assessed. The prognostic value of baseline imaging parameters for interim treatment response was also analyzed. [68Ga]Ga-PentixaFor demonstrated significantly higher lesion detection rates than [18F]FDG, particularly for gastric (72.0% vs. 40.0%) and nodal involvement (97.4% vs. 39.7%), with a superior target-to-background ratio (median TBRliver: 5.55 vs. 2.42, p < 0.01). CXCR4-targeted imaging resulted in disease upstaging in 26.8% of patients (overall stage migration: 29.3%) and led to management modifications in 56.1%. Regarding therapeutic outcomes, higher baseline [68Ga]Ga-PentixaFor SUVmax (> 7.96) was associated with lower complete remission (CR) rates. Notably, dual-tracer phenotyping further demonstrated decreasing CR rates across double-negative, single-positive, and double-positive groups (100%, 61.5%, and 36.4%, respectively). [68Ga]Ga-PentixaFor PET/CT significantly outperforms [18F]FDG in initial staging of MZL and has a substantial impact on clinical management. Importantly, dual-tracer imaging shows potential as a novel, non-invasive biomarker for in vivo phenotypic characterization, which is associated with early therapeutic outcomes and the identification of high-risk patients.


  • Open Access

    Lactate dehydrogenase/albumin ratio predicts progression of disease within 24 months (POD24) in advanced-stage extranodal natural killer/T cell lymphoma

    by Na Li, Xi Chen, Leiming Sheng, You Feng, Shihui Min, Jing Huang, Rong Luo, Liqun Zou

    Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive malignancy with poor outcomes in advanced-stage disease. Although progression of disease within 24 months (POD24) serves as a powerful predictor of poor survival in various lymphoma subtypes, its utility in advanced-stage ENKTL has not been specifically validated. This study aims to identify high-risk patients with advanced-stage ENKTL and determine the clinical factors associated with early recurrence following anti-tumor treatment. We retrospectively analyzed 119 patients with advanced-stage ENKTL. All patients received asparaginase-based chemotherapy. Of the 119 patients, 81 patients (68.1%) experienced POD24. The 5-year overall survival (OS) rate was 36.0% for the entire cohort. Patients with POD24 had significantly worse outcomes compared to non-POD24 patients (5-year OS: 10.6% vs. 81.4%; p < 0.001). The optimal thresholds for serum albumin (ALB) and lactate dehydrogenase (LDH) levels were identified as 35.5 g/Land 264 u/L, respectively, and 6.0 for lactate dehydrogenase/albumin ratio (LAR). The result identified Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥2, LDH >264 u/L, ALB 6.0, lymphocyte count 6.0 is a readily available biomarker for predicting POD24, independent of EBV-DNA status. These findings facilitate early risk stratification and may guide treatment intensification strategies in this population.

  • Open Access

    Whole-exome sequencing identifies a CD38 variant in a Chinese family with hodgkin’s lymphoma

    by Xi Chen, Li Xie, Wanchun Wu, Ming Jiang, Yi Cui, Liqun Zou

    Hodgkin’s lymphoma (HL) exhibits genetic susceptibility, but little is known about the pathogenic genes associated with the disease. Herein, we present a case of two siblings from a consanguineous Chinese family who were both diagnosed with nodular sclerosis classical HL. The female child and male child were diagnosed at the ages of 22 and 29, respectively, both presenting with involvement of the neck and mediastinal lymph nodes, and poor response or relapse shortly after the first-line treatment. Whole-exome sequencing of the four family members revealed a novel pathogenic missense mutation in the CD38 gene (c.418 C > T, p.Arg140Trp), which was found to be inherited in an autosomal recessive manner. Herein, we identified a putative pathogenic genetic variant that may be associated with HL, which will contribute to improve the understanding of the genetic molecular mechanisms underlying the disease.

  • Open Access

    The prognostic value of hemoglobin, albumin, lymphocyte, and platelet (HALP) score in low-risk and early-stage extranodal natural killer/T cell lymphoma

    by Na Li, Jing Huang, Yuping Xie, You Feng, Shihui Min, Li-Qun Zou

    Background Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive disease with grim prognosis. The hemoglobin, albumin, lymphocyte, and platelet (HALP) score has been identified as a predictive marker for prognosis in various malignancies. However, the prognostic significance of the HALP score in the context of ENKTL has yet to be established. Aims Our objective was to assess the predictive power of the initial HALP score for ENKTL patients regarding their prognosis. Methods We conducted a retrospective analysis of 296 early-stage, low-risk ENKTL patients who were newly diagnosed and treated with asparaginase-based therapies. We evaluated the significance of HALP score as a predictor of response to treatment, overall survival (OS), and progression-free survival (PFS). Results The median follow‑up for all patients was 72 months. We identified that a low HALP score was associated with a poorer Eastern Cooperative Oncology Group (ECOG) performance status (PS), the presence of B symptoms, male gender, and increased lactate dehydrogenase (LDH) levels (all p < 0.05), as well as a suboptimal response to therapy (p = 0.006). In the prognostic index of natural killer cell lymphoma (PINK) model, low-risk ENKTL patients with a HALP score below 32.6 exhibited significantly worse 5-year OS at 51.8% compared to 75.5% for those with a HALP score of 32.6 or above (p < 0.001), and 5-year PFS at 47.1% compared to 69.9% (p < 0.001). Integrating Epstein-Barr virus (EBV)-DNA titer into the PINK model led to the development of an additional prognostic index, the PINK-E model. According to this model, low-risk ENKTL patients with a HALP score below 32.6 had significantly poorer 5-year OS at 46.0% compared to 73.1% for those with a HALP score of 32.6 or above (p < 0.001), and 5-year PFS at 40.8% compared to 68.5% (p < 0.001). Conclusion Low HALP score was associated with unfavorable clinicopathological characteristics of ENKTL patients with low-risk and early-stage disease, suggesting that it may serve as an independent, negative prognostic indicator.


  • Open Access

    Differences in axillary response and treatment implications in HER2 positive node positive breast cancer during neoadjuvant HER2 targeted dual therapy

    by Exian Mou, Juan Ji, Shiwei Liu, Lan Shu, Liqun Zou, Zhuoxuan Li

    Explore whether the axillary outcomes differ among HER2 positive subgroups receiving standard dual-targeted therapy, aiming to identify subgroups exhibiting enhanced sensitivity to NAT among HER2-positive/node-positive breast cancer patients. HER2 positive female patients with biopsy-proven node-positive disease from April 2020 to May 2023 were included. All patients underwent standard Neoadjuvant HER2-targeted dual therapy and axillary lymph node dissection (ALND) at Breast Surgery Center of Sichuan Cancer Hospital. Univariate and multivariate analyses were used to identify factors associate with axillary pathological complete response (ApCR). Statistical analysis and graphing were performed using SPSS 24.0 and GraphPad Prism 9.0 software. This study enrolled 215 HER2 positive patients with a total ApCR rate of 76.7%, which included 49 HER2 2+/FISH + and 166 HER2 3 + cases with approximate ApCR rates of 63.3% and 80.7% (P = 0.011). Univariate and multivariate analysis indicated that HER2 3 + disease (OR = 2.43, 95% CI 1.21–4.88, P = 0.012), Ki-67 ≥ 20% disease (OR = 3.00, 95% CI 1.26–7.13, P = 0.013) and NAC regimen of TCb (OR = 2.71, 95% CI 1.39–5.38, P = 0.004) were more likely to achieve ApCR. Further subgroup analysis revealed that HER2 3 + patients receiving TCb regimen showed the highest ApCR rate of 88% compared to other subgroups. HER2 3 + breast cancer had a higher ApCR rate than HER2 2+/FISH + breast cancer during Neoadjuvant HER2-targeted dual therapy. HER2 positive patients could benefit from NAC regimen of TCb in axillary response.


  • Diagnosis of bone marrow involvement in angioimmunoblastic T-cell lymphoma should be based on both [ 18 F]FDG-PET/CT and bone marrow biopsy findings

    by Xinyu Liang, Chunli Yang, Minggang Su, Liqun Zou

    Objective: During the initial staging of certain lymphoma subtypes, 18 F-fluorodeoxyglucose positron emission tomography/computed tomography ([F-18]FDG-PET/CT) has become an alternative to bone marrow biopsy (BMB) for detecting bone marrow (BM) involvement. However, whether [F-18]FDG-PET/CT can accurately detect BM involvement in angioimmunoblastic T-cell lymphoma (AITL) remains unknown. Our study aimed to assess the diagnostic and prognostic capability of [F-18]FDG-PET/CT for detecting BM involvement in AITL. Methods: This retrospective study included 84 individuals newly diagnosed with AITL who underwent baseline BMB and [F-18]FDG-PET/CT. "BM involvement" was defined as one or both of the following: 1) angioimmunoblastic T-cells detected in the BM; or 2) initially heightened focal uptake having disappeared on follow-up [F-18]FDG-PET/CT. The ability of [F-18]FDG-PET/CT to detect BM cancerous lesions was respectively analyzed by BM involvement confirmed by BMB or the aforementioned definition as the reference standard. The patients' clinical characteristics and survival and prognostic outcomes were respectively analyzed. Results: Of the 84 participants, five (6.0%) displayed positive BMB and PET/BM results, 17 (20.2%) had BMB-positive but PET/BM-negative results, eight (9.5%) showed BMB-negative but PET/BM-positive outcomes, and 54 (64.3%) displayed negative BMB and PET/BM outcomes. Using pre-defined BM involvement as the reference standard, [F-18]FDG-PET/CT exhibited a specificity of 100%, sensitivity of 40%, negative predictive value (NPV) of 75%, and positive predictive value (PPV) of 100%. In contrast, using BMB-detected BM involvement as reference, [F-18]FDG-PET/CT exhibited a sensitivity, specificity, PPV, and NPV of 38.5%, 76.1%, 22.7%, and 87.1%, respectively. Among patients with PET/BM-positive and BMB-negative outcomes, 62.5% (5/8) underwent upstaging from III to IV. In 58.8% (10/17) of patients who were initially diagnosed with stage II/III disease based on the [F-18]FDG-PET/CT results, repeat BMB resulted in upstaging to IV. PET/BM-negative patients had a higher 3-year progression-free survival rate (38.3% vs. 22.8%, p = 0.018) and 3-year overall survival rate (64.4% vs. 34.6%, p = 0.011) than PET/BM-positive patients. Conclusion: In AITL patients, PET/BM-positive results may obviate the necessity for repeat BMB to ascertain confirm BM involvement. PET/BM-negative results do not definitively exclude BM involvement. The combined use of [F-18]FDG-PET/CT and BMB can increase the diagnostic accuracy of BM involvement for AITL patients.


  • Open Access

    Potential Mechanism of Tibetan Medicine Liuwei Muxiang Pills against Colorectal Cancer: Network Pharmacology and Bioinformatics Analyses

    by Shaochong Qi, Xinyu Liang, Zijing Wang, Haoran Jin, Liqun Zou, Jinlin Yang

    This study aimed to explore the mechanism through which Tibetan medicine Liuwei Muxiang (LWMX) pills acts against colorectal cancer (CRC). We firstly retrieved the active ingredients and the correlated targets of LWMX pills from public databases. The CRC-related targets were determined through bioinformatic analysis of a public CRC dataset. By computing the intersection of the drug-specific and disease-related targets, LWMX pill–CRC interaction networks were constructed using the protein–protein interaction (PPI) method and functional enrichment analysis. Subsequently, we determined the hub genes using machine learning tools and further verified their critical roles in CRC treatment via immune infiltration analysis and molecular docking studies. We identified 81 active ingredients in LWMX pills with 614 correlated targets, 1877 differentially expressed genes, and 9534 coexpression module genes related to CRC. A total of 5 target hub genes were identified among the 108 intersecting genes using machine learning algorithms. The immune infiltration analysis results suggested that LWMX pills could affect the CRC immune infiltration microenvironment by regulating the expression of the target hub genes. Finally, the molecular docking outcomes revealed stable binding affinity between all target hub proteins and the primary active ingredients of LWMX pills. Our findings illustrate the anti-CRC potential and the mechanism of action of LWMX pills and provide novel insights into multitarget medication for CRC treatment.


  • Open Access

    Genetically determined telomere length as a risk factor for hematological malignancies: evidence from Mendelian randomization analysis

    by Tian Fang, Zhihao Zhang, Kexing Ren, Liqun Zou

    Background: Over the past years, the exact correlation between telomere length and hematological malignancies was still not fully understood. Methods: We performed a two-sample Mendelian randomization study to investigate the causal relationship between telomere length and hematological malignancies. We selected genetic instruments associated with telomere length. The genetic associations for lymphoid and hematopoietic malignant neoplasms were obtained from the most recent publicly accessible FinnGen study R9 data. Inverse variant weighted (IVW) analysis was adopted as the primary method, and we also performed the weighted-median method and the MR-Egger, and MRPRESSO methods as sensitive analysis. Results: Significant associations have been observed between telomere length and primary lymphoid (IVW: OR = 1.52, P = 2.11 × 10−6), Hodgkin lymphoma (IVW: OR = 1.64, P = 0.014), non-Hodgkin lymphoma (IVW: OR = 1.70, P = 0.002), B-cell lymphoma (IVW: OR = 1.57, P = 0.015), non-follicular lymphoma (IVW: OR = 1.58, P = 1.7 × 10−3), mantle cell lymphoma (IVW: OR = 3.13, P = 0.003), lymphoid leukemia (IVW: OR = 2.56, P = 5.92E-09), acute lymphocytic leukemia (IVW: OR = 2.65, P = 0.021) and chronic lymphocytic leukemia (IVW: OR = 2.80, P = 8.21 × 10−6), along with multiple myeloma (IVW: OR = 1.85, P = 0.016). Conclusion: This MR study found a significant association between telomere length and a wide range of hematopoietic malignancies. But no substantial impact of lymphoma and hematopoietic malignancies on telomere length has been detected.